Cns Pharmaceuticals Inc CNSP

$5.32 +0.08 (1.61%)

Valuation

Market cap
7,658,000
Revenue TTM
$0
Net income TTM
$-15,850,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
10,900
Avg volume
6,018
Day's range
$5.11 – $5.40
Shares out
1,461,000
Stochastic %K
74%
Beta
3.10
Analysts
Strong Sell
Price target
$10.00

Price

Company profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblasto...

Show more

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
800 946 9185
Website
https://cnspharma.com
Address
2100 West Loop South, Suite 900, Houston, United States

Latest news

Stocktwits

focafoca99 Oct 2, 12:15 PM
$CNSP announced its annual meeting, electing six new directors and expanding the 2020 Equity Plan by 650,000 shares.
0 replies
NetworkNewsWire Sep 8, 8:00 PM
Laser Therapy Shows Promise in Treating Brain Cancer $CNSP https://ibn.fm/Arlsc #tinygems #stocks
0 replies
NetworkNewsWire Sep 4, 5:59 PM
Timing of Brain Metastasis Predicts Survival of Colorectal Cancer Patients $CNSP #BioMed #Brain #Cancer https://ibn.fm/nCBEp
0 replies
VirtualInvestor Sep 1, 3:40 PM
$CNSP Chief Business Officer, Dylan Wenke, joins Virtual Investor’s “What This Means” series to discuss the Company’s business development strategy as it builds an oncology or neurology pipeline with best-in-class potential. https://vimeo.com/1222840808/9bb3667cd1
0 replies
Cns_pharma Sep 1, 3:34 PM
$CNSP Details Business Development Strategy Driving Its Next Phase of Growth Chief Business Officer, Dylan Wenke, Participates in Virtual Investor “What This Means” Segment Access the segment here: https://virtualinvestorco.com/cnsp/ Press Release: https://cnspharma.com/cns-pharmaceuticals-details-business-development-strategy-driving-its-next-phase-of-growth/
0 replies
NetworkNewsWire Aug 27, 5:10 PM
Covid-19 Vaccine Could Extend Survival of Brain Cancer Patients $CNSP #BioMed #Covid #Cancer https://ibn.fm/ACwVX
0 replies
VirtualInvestor Aug 27, 2:21 PM
$CNSP Participates in the Virtual Investor "Why Now" On-Demand Conference Hope starts with pursuing what's possible. https://vimeo.com/1221551759/6f89b281ba?fl=ml&fe=ec
0 replies
Cns_pharma Aug 27, 2:13 PM
$CNSP Participates in the Virtual Investor "Why Now" On-Demand Conference Access the webcast here: https://virtualinvestorco.com/why-now/ Press Release: https://cnspharma.com/cns-pharmaceuticals-participates-in-the-virtual-investor-why-now-on-demand-conference/
0 replies